KLK3 and prostate carcinoma: In another study, TDsEVs were encoded with two tumour antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), which increased the frequency of PAP-specific T cells and improved antitumour efficacy in a PSA-expressing prostate cancer model [183].